Grown Rogue International (GRUSF) Share-based Compensation (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Share-based Compensation came in at $154994.0 in Q1 2026, down 89.21% year-on-year from $1.4 million in Q1 2025, and up 100.0% quarter-over-quarter from -$1969.7 billion in Q4 2025.
Grown Rogue International (GRUSF) Share-based Compensation (2009 - 2026) Analysis & Trends
Grown Rogue International's Share-based Compensation history runs 14 years deep, the most recent figure standing at $154994.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 89.21% year-over-year to $154994.0 in Q1 2026; TTM through Mar 2026 was -$157635.0, a 100.0% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, down 30.18% from the prior year.
- Share-based Compensation grew to $154994.0 in Q1 2026 per GRUSF's latest filing, from -$1969.7 billion in the prior quarter.
- Across five years, Share-based Compensation topped out at $1969.7 billion in Q3 2025 and bottomed at -$1969.7 billion in Q4 2025.
- The 5-year median for Share-based Compensation is $75874.0 (2023), against an average of -$27.1 billion.
- Biggest YoY gain for Share-based Compensation was 911452470.55% in 2025; the steepest drop was 419.48% in 2025.
- Year by year, Share-based Compensation stood at $7499.0 in 2022, then jumped by 3773.73% to $290491.0 in 2023, then sank by 130529579.8% to -$379.2 billion in 2024, then slumped by 419.48% to -$1969.7 billion in 2025, then surged by 100.0% to $154994.0 in 2026.
- Per Business Quant, the three latest GRUSF Share-based Compensation figures stand at $154994.0 (Q1 2026), -$1969.7 billion (Q4 2025), and $1969.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 154,994.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 154,994.00 |
| Mar 31, 2026 | 154,994.00 |
| Dec 31, 2025 | -1,969.73 Bn |
| Dec 31, 2025 | -1,969.73 Bn |
| Sep 30, 2025 | 1,969.73 Bn |
| Sep 30, 2025 | 1,969.73 Bn |
| Jun 30, 2025 | 6,433.00 |
| Jun 30, 2025 | 6,433.00 |
| Mar 31, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | -379.18 Bn |
| Dec 31, 2024 | -379.18 Bn |
| Sep 30, 2024 | 216,109.28 |
| Sep 30, 2024 | 216,109.28 |
| Jun 30, 2024 | 20,607.93 |
| Jun 30, 2024 | 20,607.93 |
| Mar 31, 2024 | 56,185.00 |
| Mar 31, 2024 | 56,185.00 |
| Oct 31, 2023 | 290,491.00 |
| Oct 31, 2023 | 290,491.00 |